These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23719202)

  • 1. Sieve analysis in HIV-1 vaccine efficacy trials.
    Edlefsen PT; Gilbert PB; Rolland M
    Curr Opin HIV AIDS; 2013 Sep; 8(5):432-6. PubMed ID: 23719202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
    Gartland AJ; Li S; McNevin J; Tomaras GD; Gottardo R; Janes H; Fong Y; Morris D; Geraghty DE; Kijak GH; Edlefsen PT; Frahm N; Larsen BB; Tovanabutra S; Sanders-Buell E; deCamp AC; Magaret CA; Ahmed H; Goodridge JP; Chen L; Konopa P; Nariya S; Stoddard JN; Wong K; Zhao H; Deng W; Maust BS; Bose M; Howell S; Bates A; Lazzaro M; O'Sullivan A; Lei E; Bradfield A; Ibitamuno G; Assawadarachai V; O'Connell RJ; deSouza MS; Nitayaphan S; Rerks-Ngarm S; Robb ML; Sidney J; Sette A; Zolla-Pazner S; Montefiori D; McElrath MJ; Mullins JI; Kim JH; Gilbert PB; Hertz T
    J Virol; 2014 Aug; 88(15):8242-55. PubMed ID: 24829343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.
    Edlefsen PT; Rolland M; Hertz T; Tovanabutra S; Gartland AJ; deCamp AC; Magaret CA; Ahmed H; Gottardo R; Juraska M; McCoy C; Larsen BB; Sanders-Buell E; Carrico C; Menis S; Kijak GH; Bose M; ; Arroyo MA; O'Connell RJ; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Rerks-Ngarm S; Robb ML; Kirys T; Georgiev IS; Kwong PD; Scheffler K; Pond SL; Carlson JM; Michael NL; Schief WR; Mullins JI; Kim JH; Gilbert PB
    PLoS Comput Biol; 2015 Feb; 11(2):e1003973. PubMed ID: 25646817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials.
    Fiore-Gartland A; Kullman N; deCamp AC; Clenaghan G; Yang W; Magaret CA; Edlefsen PT; Gilbert PB
    Bioinformatics; 2017 Aug; 33(15):2386-2388. PubMed ID: 28379332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
    Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C
    Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 phylogenetics and vaccines.
    Rolland M
    Curr Opin HIV AIDS; 2019 May; 14(3):227-232. PubMed ID: 30925535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
    Rolland M; Gilbert P
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
    Zolla-Pazner S; Michael NL; Kim JH
    Lancet HIV; 2021 Jul; 8(7):e449-e452. PubMed ID: 34029515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
    Dommaraju K; Kijak G; Carlson JM; Larsen BB; Tovanabutra S; Geraghty DE; Deng W; Maust BS; Edlefsen PT; Sanders-Buell E; Ratto-Kim S; deSouza MS; Rerks-Ngarm S; Nitayaphan S; Pitisuttihum P; Kaewkungwal J; O'Connell RJ; Robb ML; Michael NL; Mullins JI; Kim JH; Rolland M
    PLoS One; 2014; 9(10):e111334. PubMed ID: 25350851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
    Tomaras GD; Plotkin SA
    Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational research insights from completed HIV vaccine efficacy trials.
    Tieu HV; Rolland M; Hammer SM; Sobieszczyk ME
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S150-4. PubMed ID: 23764628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
    Gray GE; Allen M; Moodie Z; Churchyard G; Bekker LG; Nchabeleng M; Mlisana K; Metch B; de Bruyn G; Latka MH; Roux S; Mathebula M; Naicker N; Ducar C; Carter DK; Puren A; Eaton N; McElrath MJ; Robertson M; Corey L; Kublin JG;
    Lancet Infect Dis; 2011 Jul; 11(7):507-15. PubMed ID: 21570355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells.
    Fisher L; Zinter M; Stanfield-Oakley S; Carpp LN; Edwards RW; Denny T; Moodie Z; Laher F; Bekker LG; McElrath MJ; Gilbert PB; Corey L; Tomaras G; Pollara J; Ferrari G
    Front Immunol; 2019; 10():2741. PubMed ID: 31827470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current views on the potential for development of a HIV vaccine.
    Cohen KW; Frahm N
    Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New concepts in HIV-1 vaccine development.
    Stephenson KE; D'Couto HT; Barouch DH
    Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No acquisition: a new ambition for HIV vaccine development?
    Lakhashe SK; Silvestri G; Ruprecht RM
    Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.